Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 11, 1999, Pages 1419-1427

  Jones, R H ^a   Holtmann, G ^e   Rodrigo, L ^b   Ehsanullah, R S B ^c   Crompton, P M ^d   Jacques, L A ^c   Mills, Jane G ^c,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Gastroenterol Clinical Development   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Gastroenterol Clin Devmt Glaxo W ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; DIGESTIVE TRACT SPASMOLYTIC AGENT; MEBEVERINE; SEROTONIN ANTAGONIST;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALAISE; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; VIRUS INFECTION;

ADOLESCENT; ADULT; CARBOLINES; COLONIC DISEASES, FUNCTIONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PAIN; PARASYMPATHOLYTICS; PHENETHYLAMINES; SEROTONIN ANTAGONISTS;

EID: 0032749795     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00678.x     Document Type: Article

References (32)

1. 1 Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992; 304: 87-90.
2. 2 Harvey R, Read A, Salih Y. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983; 1: 632-4.
3. 3 Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60: 77-81.
4. 4 Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1019-30.
5. 5 Farthing M. Irritable bowel, irritable body, irritable brain? Br Med J 1995; 310: 171-5.
6. 6 Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37.
7. 7 Thompson W, Longstreth G, Drossman D et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. II): 43-7.
8. 8 Klein K. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-41.
9. 9 Pattee PL, Thompson WG. Drug treatment of the irritable bowel syndrome. Drugs 1992; 44: 200-6.
10. 10 Bardhan K, Bodemar G, Geldof H et al. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Gastroenterology 1996; 110; A630 (Abstract).
11. 3-receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59.
12. 3-receptor antagonist. Gastroenterology 1999; 116: A1036(Abstract).
13. 13 Gershon M. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13: 15-30.
14. 14 Delvaux M, Louvel D, Mamet JP et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
15. 3 antagonism (ondansetron). Digestion 1996; 57: 478-83.
16. 3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 175-80.
17. 17 Zighelboim J, Talley NJ, Phillips SF et al. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-27.
18. 18 Baume P. Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med 1972; 2: 34-6.
19. 19 Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1996; 10: 787-93.
20. 20 Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J 1965; 5466: 848-51.
21. 21 Thompson W, Creed F, Drossman D et al. Functional bowel disorders and functional abdominal pain. Gastrointest J 1992; 5: 75-91.
22. 22 Harding JP, Hamm LR, Ehsanullah RSB et al. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1073-6.
23. 23 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 1959; 22: 719-48.
24. 24 van Elteren P. On the combination of independent two sample tests of Wilcoxon. Bull Int Stat Inst 1960; 37: 351-61.
25. 25 Dan Hertog A, Vanden Akker J. Modification of alpha 1-receptor operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol 1987; 138: 367-74.
26. 26 Poynard T, Naveau S, Mory B et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499-510.
27. 27 Le Gal M, Pelouz C. Colopathie fonctionelle. Une étude multicentrique rassemblant 1147 malades a confirmé l'efficacité de Duspatalin' suspension, sur les symptômes de colopathie, ainsi qu'une bonne tolérance et une excellente acceptabilité. Impact Med 1989; 3: 70-3.
28. 28 Guyot P. Efficacité de la mébévérine (Duspatalin' 200 mg gélule) chez des patients présentant des troubles fonctionnels intestinaux: résultats d'une étude descriptive en fonction des dillérents sous-groupes symptomatiques. Act Méd Int Gastroentérol 1997; 11: 40-5.
29. 29 Mangel AW, Hahn BA, Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998; 26: 76-81.
30. 30 Mangel AW, Northcutt AR, Kong S et al. Validation of adequate relief as an endpoint in irritable bowel syndrome. Gastroenterology 1999; 116: A1035(Abstract).
31. 31 Northcutt A, Harding J, Kong S et al. Urgency as an endpoint in IBS. Gastroenterology 1999; 116: A1036(Abstract).
32. 32 Watson MW, Lacey LA, McSorley D, Northcutt A, Mangel A. Impact of alosetron on health-related quality of life (HRQOL) in female patients with irritable bowel syndrome (IBS). Am J Gastroenteol 1999; 94: 2762 (Abstract 741).